PEGylation of therapeutic proteins

Since the first PEGylated product was approved by the Food and Drug Administration in 1990, PEGylation has been widely used as a post‐production modification methodology for improving biomedical efficacy and physicochemical properties of therapeutic proteins. Applicability and safety of this technology have been proven by use of various PEGylated pharmaceuticals for many years. It is expected that PEGylation, as the most established technology for extension of drug residence in the body, will play an important role in the next generation therapeutics, such as peptides, protein nanobodies and scaffolds, which due to their diminished molecular size need half‐life extension. This review focuses on several factors important in the production of PEGylated biopharmaceuticals enabling efficient preparation of highly purified PEG‐protein conjugates that have to meet stringent regulatory criteria for their use in human therapy. Areas addressed are PEG properties, the specificity of PEGylation reactions, separation and large‐scale purification, the availability and analysis of PEG reagents, analysis of PEG‐protein conjugates, the consistency of products and processes and approaches used for rapid screening of pharmacokinetic properties of PEG‐protein conjugates.

[1]  A. Zydney,et al.  Ultrafiltration characteristics of pegylated proteins , 2006, Biotechnology and bioengineering.

[2]  A. Lim,et al.  Applications of mass spectrometry for the structural characterization of recombinant protein pharmaceuticals. , 2007, Mass spectrometry reviews.

[3]  C. Won,et al.  PEG-modified biopharmaceuticals , 2009 .

[4]  M. Gore,et al.  Pegylated interferon alfa-2b treatment for patients with solid tumors: a phase I/II study. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  I. Mahmood,et al.  Pharmacokinetic and Pharmacodynamic Considerations in the Development of Therapeutic Proteins , 2005, Clinical pharmacokinetics.

[6]  M. Hershfield,et al.  Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase , 2005, Arthritis research & therapy.

[7]  J. M. Harris,et al.  Effect of pegylation on pharmaceuticals , 2003, Nature Reviews Drug Discovery.

[8]  D. Wyss,et al.  Structural and biological characterization of pegylated recombinant interferon alpha-2b and its therapeutic implications. , 2002, Advanced drug delivery reviews.

[9]  H. Chokshi,et al.  Size exclusion chromatography with Corona charged aerosol detector for the analysis of polyethylene glycol polymer. , 2009, Journal of chromatography. A.

[10]  S. Jevševar,et al.  Size of Pegylated Protein Conjugates Studied by Various Methods , 2008 .

[11]  A. Hunter,et al.  Comparison of strong anion-exchangers for the purification of a PEGylated protein. , 2007, Journal of chromatography. A.

[12]  J. V. Van Alstine,et al.  Prediction of the viscosity radius and the size exclusion chromatography behavior of PEGylated proteins. , 2004, Bioconjugate chemistry.

[13]  C. Verhoest,et al.  Cancer therapy with chemically modified enzymes. I. Antitumor properties of polyethylene glycol-asparaginase conjugates. , 1984, Cancer biochemistry biophysics.

[14]  Darin J. Smith,et al.  Site-specific PEGylation of engineered cysteine analogues of recombinant human granulocyte-macrophage colony-stimulating factor. , 2005, Bioconjugate chemistry.

[15]  J. V. Alstine,et al.  PEG-proteins: Reaction engineering and separation issues , 2006 .

[16]  C Simone Fishburn,et al.  The pharmacology of PEGylation: balancing PD with PK to generate novel therapeutics. , 2008, Journal of pharmaceutical sciences.

[17]  S. Brocchini,et al.  Site-specific PEGylation of protein disulfide bonds using a three-carbon bridge. , 2007, Bioconjugate chemistry.

[18]  A. Azadi,et al.  Designing PEGylated therapeutic molecules: advantages in ADMET properties , 2008, Expert opinion on drug discovery.

[19]  H. de Haard,et al.  Properties, production, and applications of camelid single-domain antibody fragments , 2007, Applied Microbiology and Biotechnology.

[20]  S. Brocchini,et al.  Site-specific PEGylation of native disulfide bonds in therapeutic proteins , 2006, Nature chemical biology.

[21]  S. Zalipsky,et al.  Succinimidyl Carbonates of Polyethylene Glycol: Useful Reactive Polymers for Preparation of Protein Conjugates , 1991 .

[22]  R. Mehvar.  Modulation of the pharmacokinetics and pharmacodynamics of proteins by polyethylene glycol conjugation. , 2000, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.

[23]  R. Bayer,et al.  GlycoPEGylation of recombinant therapeutic proteins produced in Escherichia coli. , 2006, Glycobiology.

[24]  F. Davis,et al.  Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase. , 1977, The Journal of biological chemistry.

[25]  S. Zalipsky,et al.  Evaluation of a new reagent for covalent attachment of polyethylene glycol to proteins.“ , 1992, Biotechnology and applied biochemistry.

[26]  D. Filpula,et al.  Releasable PEGylation of proteins with customized linkers. , 2008, Advanced drug delivery reviews.

[27]  J. Bi,et al.  Reproducible preparation and effective separation of PEGylated recombinant human granulocyte colony-stimulating factor with novel "PEG-pellet" PEGylation mode and ion-exchange chromatography. , 2005, Journal of biotechnology.

[28]  G. V. van Dongen,et al.  Nanobodies in therapeutic applications. , 2007, Current opinion in molecular therapeutics.

[29]  F. Veronese,et al.  Site-specific modification and PEGylation of pharmaceutical proteins mediated by transglutaminase. , 2008, Advanced drug delivery reviews.

[30]  P. Caliceti,et al.  Branched and Linear Poly(Ethylene Glycol): Influence of the Polymer Structure on Enzymological, Pharmacokinetic, and Immunological Properties of Protein Conjugates , 1997 .

[31]  J. Chern,et al.  Efficient clearance of poly(ethylene glycol)-modified immunoenzyme with anti-PEG monoclonal antibody for prodrug cancer therapy. , 2000, Bioconjugate chemistry.

[32]  M. Montaudo,et al.  Characterization of synthetic polymers by MALDI-MS , 2006 .

[33]  Deirdre Murphy Piedmonte,et al.  Formulation of Neulasta (pegfilgrastim). , 2008, Advanced drug delivery reviews.

[34]  Hong Zhao,et al.  Structure-function engineering of interferon-beta-1b for improving stability, solubility, potency, immunogenicity, and pharmacokinetic properties by site-selective mono-PEGylation. , 2006, Bioconjugate chemistry.

[35]  G. Molineux.  The design and development of pegfilgrastim (PEG-rmetHuG-CSF, Neulasta). , 2004, Current pharmaceutical design.

[36]  D. Szymkowski,et al.  Creating the next generation of protein therapeutics through rational drug design. , 2005, Current opinion in drug discovery & development.

[37]  C. Fee.  Size comparison between proteins PEGylated with branched and linear poly(ethylene glycol) molecules , 2007, Biotechnology and bioengineering.

[38]  P. Serruys,et al.  Effect of an anti‐PDGF‐β‐receptor‐blocking antibody on restenosis in patients undergoing elective stent placement , 2003, International journal of cardiovascular interventions.

[39]  Darin J. Smith,et al.  A long-acting, highly potent interferon alpha-2 conjugate created using site-specific PEGylation. , 2005, Bioconjugate chemistry.

[40]  A. Schacher,et al.  Isolation, structural characterization, and antiviral activity of positional isomers of monopegylated interferon alpha-2a (PEGASYS). , 2003, Protein expression and purification.

[41]  V. Gaberc-Porekar,et al.  Obstacles and pitfalls in the PEGylation of therapeutic proteins. , 2008, Current opinion in drug discovery & development.

[42]  M. Kurfürst.  Detection and molecular weight determination of polyethylene glycol-modified hirudin by staining after sodium dodecyl sulfate-polyacrylamide gel electrophoresis. , 1992, Analytical biochemistry.

[43]  A. Sehon.  Suppression of Antibody Responses by Conjugates of Antigens and Monomethoxypoly(Ethylene Glycol) , 1991 .

[44]  P. Caliceti,et al.  Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates. , 2003, Advanced drug delivery reviews.

[45]  M. Seman,et al.  Single domain antibodies: promising experimental and therapeutic tools in infection and immunity , 2009, Medical Microbiology and Immunology.

[46]  A. Whitty,et al.  N-terminally PEGylated human interferon-beta-1a with improved pharmacokinetic properties and in vivo efficacy in a melanoma angiogenesis model. , 2006, Bioconjugate chemistry.

[47]  G. Shopp,et al.  Short communication: renal tubular vacuolation in animals treated with polyethylene-glycol-conjugated proteins. , 1998, Toxicological sciences : an official journal of the Society of Toxicology.

[48]  A. Judge,et al.  Hypersensitivity and loss of disease site targeting caused by antibody responses to PEGylated liposomes. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[49]  D. Guyer,et al.  Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease , 2006, Nature Reviews Drug Discovery.

[50]  T. Ishida,et al.  Anti-PEG IgM elicited by injection of liposomes is involved in the enhanced blood clearance of a subsequent dose of PEGylated liposomes. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[51]  M. Bentley,et al.  Chemistry for peptide and protein PEGylation. , 2002, Advanced drug delivery reviews.

[52]  S. Moghimi,et al.  Poly(ethylene glycol)s generate complement activation products in human serum through increased alternative pathway turnover and a MASP-2-dependent process. , 2008, Molecular immunology.

[53]  P. Caliceti,et al.  Immunological properties of uricase conjugated to neutral soluble polymers. , 2001, Bioconjugate chemistry.

[54]  M. Hershfield,et al.  Adenosine deaminase deficiency with late onset of recurrent infections: response to treatment with polyethylene glycol-modified adenosine deaminase. , 1988, The Journal of pediatrics.

[55]  Zhi-xin Xu,et al.  Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C. , 2001, Bioconjugate chemistry.

[56]  E. Åkerblom,et al.  Antibodies against polyethylene glycol produced in animals by immunization with monomethoxy polyethylene glycol modified proteins. , 1983, International archives of allergy and applied immunology.

[57]  D. Humphreys,et al.  Alternative antibody Fab' fragment PEGylation strategies: combination of strong reducing agents, disruption of the interchain disulphide bond and disulphide engineering. , 2007, Protein engineering, design & selection : PEDS.

[58]  F. Kawai,et al.  Microbial degradation of polyethers , 2001, Applied Microbiology and Biotechnology.

[59]  David J Brayden,et al.  Advances in PEGylation of important biotech molecules: delivery aspects , 2008, Expert opinion on drug delivery.

[60]  Steven W. Martin,et al.  Design of PEGylated soluble tumor necrosis factor receptor type I (PEG sTNF-RI) for chronic inflammatory diseases. , 2003, Advanced drug delivery reviews.

[61]  M. Schiefermeier,et al.  Correlations between in vitro potency of polyethylene glycol-protein conjugates and their chromatographic behavior. , 2009, Analytical biochemistry.

[62]  G. Pasut,et al.  Polymer-drug conjugation, recent achievements and general strategies , 2007 .

[63]  Darin J. Smith,et al.  A Long-Acting, Highly Potent Interferon α-2 Conjugate Created Using Site-Specific PEGylation , 2005 .

[64]  Kang-Choon Lee,et al.  Emerging PEGylated drugs , 2009, Expert opinion on emerging drugs.

[65]  Mariangela Spitali,et al.  Therapeutic antibody fragments with prolonged in vivo half-lives , 1999, Nature Biotechnology.

[66]  G. Gregoriadis,et al.  Improving the therapeutic efficacy of peptides and proteins: a role for polysialic acids. , 2005, International journal of pharmaceutics.

[67]  J. Peter-Katalinic,et al.  Structural characterization of PEGylated rHuG-CSF and location of PEG attachment sites. , 2007, Journal of pharmaceutical and biomedical analysis.

[68]  M. Treuheit,et al.  Mono-N-terminal poly(ethylene glycol)-protein conjugates. , 2002, Advanced drug delivery reviews.

[69]  Michaela Gebauer,et al.  Engineered protein scaffolds as next-generation antibody therapeutics. , 2009, Current opinion in chemical biology.

[70]  J. Seely,et al.  Making site-specific PEGylation work: Purification and analysis of PEGylated protein pharmaceuticals present many challenges , 2005 .

[71]  J. Seely,et al.  Use of ion-exchange chromatography and hydrophobic interaction chromatography in the preparation and recovery of polyethylene glycol-linked proteins. , 2001, Journal of chromatography. A.

[72]  Effect of cytochrome P-450 inhibition and stimulation on intensity of polyethylene degradation in microsomal fraction of mouse and rat livers. , 1990, Biomaterials.

[73]  A. Skerra.  Alternative non-antibody scaffolds for molecular recognition. , 2007, Current opinion in biotechnology.

[74]  P. Schultz,et al.  In vivo incorporation of an alkyne into proteins in Escherichia coli. , 2005, Bioorganic & medicinal chemistry letters.

[75]  S. Nuttall,et al.  Display scaffolds: protein engineering for novel therapeutics. , 2008, Current opinion in pharmacology.

[76]  H. Sato,et al.  Enzymatic procedure for site-specific pegylation of proteins. , 2002, Advanced drug delivery reviews.

[77]  F. Perez-Ruiz,et al.  PEG-uricase in the management of treatment-resistant gout and hyperuricemia. , 2008, Advanced drug delivery reviews.

[78]  F. Veronese,et al.  Transglutaminase-mediated PEGylation of proteins: direct identification of the sites of protein modification by mass spectrometry using a novel monodisperse PEG. , 2009, Bioconjugate chemistry.

[79]  F. Davis,et al.  Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol. , 1977, The Journal of biological chemistry.